Shopping Cart
Remove All
Your shopping cart is currently empty
CSLP43
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T218689 Copy Product Info
🥰Excellent
CSLP43 is a selective inhibitor of RIPK2 and XIAP, presenting an IC50 of 19.9 nM for human RIPK2. It binds to the ATP binding pocket of RIPK2, disrupting interactions with the XIAPBIR2 or cIAP1BIR2 domains. CSLP43 effectively inhibits RIPK2 ubiquitination, NOD1- and NOD2-dependent inflammatory signaling pathways, as well as NF-κB activation associated with NOD agonists. It specifically targets NOD1/NOD2 signaling pathways without affecting the kinase activity of RIPK1 or RIPK3. CSLP43 is applicable in research related to Crohn's disease, Blau syndrome, early-onset sarcoidosis, and early-onset inflammatory bowel disease.
CSLP43
Cas No. 2244988-80-3
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | CSLP43 is a selective inhibitor of RIPK2 and XIAP, presenting an IC50 of 19.9 nM for human RIPK2. It binds to the ATP binding pocket of RIPK2, disrupting interactions with the XIAPBIR2 or cIAP1BIR2 domains. CSLP43 effectively inhibits RIPK2 ubiquitination, NOD1- and NOD2-dependent inflammatory signaling pathways, as well as NF-κB activation associated with NOD agonists. It specifically targets NOD1/NOD2 signaling pathways without affecting the kinase activity of RIPK1 or RIPK3. CSLP43 is applicable in research related to Crohn's disease, Blau syndrome, early-onset sarcoidosis, and early-onset inflammatory bowel disease. |
| Targets & IC50 | RIPK2:19.9 nM |
| In vitro | CSLP43 inhibits NOD2-mediated NF-κB activation in HEKBlue hNOD2 cells with an IC50 of 1.3 nM. It binds to intracellular RIPK2 in HEKBlue cells with an IC50 of 10.1 nM and a residence time of 106.9 minutes. CSLP43 (0-1 μM; 4 h) suppresses L18-MDP-induced CXCL8 production in U2OS/NOD2 cells and inhibits MDP-induced TNF release in RAW264.7 macrophages with an IC50 of 1.2 nM. |
| Molecular Weight | 511.64 |
| Formula | C26H33N5O4S |
| Cas No. | 2244988-80-3 |
| Smiles | O=S(=O)(NC=1C=C(C=C(OC)C1OC)C2=CC(=CN=C2N)C=3C=CC(=CC3)N4CCNCC4)CCC |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: CSLP43 in vitro | CSLP43 formula | CSLP43 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.